SEP 30 2005 INFO

INFORMATION DISCLOSURE STATEMENT

Applicant: Whitehead et al.

App. No : 10/719,547

Filed: November 21, 2003

For : DEVELOPMENT OF MUTATIONS

USEFUL FOR ATTENUATING

DENGUE VIRUSES AND CHIMERIC

DENGUE VIRUSES

Examiner : Chen, Stacy Brown

Art Unit : 1648

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 11 references to be considered by the Examiner. Also enclosed are 11 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/28/05

By:___

Nancy W. Vensko

Registration No. 36,298

Attorney of Record

Customer No. 45,311

(805) 547-5580

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Multiple sheets used when necessary)

SHEET 1 OF 2

Application No. 10/719,547 Filing Date November 21, 2003 First Named Inventor Whitehead, Stephen S. 1648 **Art Unit** Chen, Stacy Brown Examiner NIH214.001C1 Attorney Docket No.

SEP 30 7005 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines Where Examiner **Document Number** Cite **Publication Date** Number - Kind Code (if known) Name of Patentee or Applicant Relevant Passages or Relevant MM-DD-YYYY initials No. Figures Appear Example: 1,234,567 B1

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	τ1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	BLANEY, Jr., J.E. et al. (2001) "Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice" <i>J. Virol.</i> 75 :9731-9740.	
	2	BLANEY, Jr. J.E. et al. (2002) "Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and an SCID mice transplanted with human liver cells" Virology 300:125-139.	
	3	BLANEY, Jr. J.E. et al. (2003) "Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric Dengue virus type 2/4 vaccine candidate in Vero cells" <i>Vaccine</i> 21:4317-4327.	
	4	BLANEY, Jr. J.E. et al. (2003) "Temperature sensitive mutations in the genes encoding the ns1, ns2a, and ns5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice" <i>Arch. Virol.</i> 148 :999-1006.	
	5	BLANEY, Jr. J.E. et al. (2004) "Genetically modified, live attenuated dengue virus type 3 vaccine candidates" <i>Am. J. Trop. Med. Hyg.</i> 71:811-821	
	6	BLANEY, Jr. J.E. et al. (2005) "Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys" J. Virol. 79 :5516-5528.	
	7	HANLEY, K.A. et al. (2002) "Paired charge-to-alanine mutagenesis of dengue virus type 4 ns5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes" <i>J. Virol.</i> 76 :525-531.	
	8	HANLEY, K.A. et al. (2003) "A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the ns4b protein of dengue virus type 4" Virology 312:222-232.	
	9	HANLEY, K.A. et al. (2004) "Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity" <i>Vaccine</i> 22:3440-3448.	
	10	WHITEHEAD, S.S. et al. (2003) "A live attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys" <i>J. Virol.</i> 77 :1653-1657.	

Examiner	Signature
----------	-----------

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08 Equivalent

				Application No.	10/719,547		
	INFORMATION DISCLOSURE			Filing Date	November 21, 2003		
	CT	· ^ T i	EMENT BY APPLICANT	First Named Inventor	Whitehead, Stephen S.		
_	(DE)	ΑП	EMENT BY APPLICANT	Art Unit	1648		
0	40	(Multi	ple sheets used when necessary)	Examiner	Chen, Stacy Brown		
	_	3/	SHEET 2 OF 2	Attorney Docket No.	NIH214.001C1		
ς	P 3 0 1005	ונט					
3		NON PATENT LITERATURE DOCUMENTS					
Sec.	Examiner initials	Cite No.	tom (hook magazing journal carial symposium catalog etc.) date nage(s) volume-issue				
	WHITEHEAD, S.S. et al. (2003) "Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhese monkeys" <i>Vaccine</i> 21:4307-4316.						

1957043:vr 092705

Examiner Signature

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.